Advertisement
Home »

JAK1 Inhibitor Meets Primary Endpoint in Prurigo Nodularis Trial

Mar 19, 2024

REFERENCES & ADDITIONAL READING

Metz M. Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: results from a randomized, double-blind, placebo-controlled phase 2 study. Presented at: AAD 2024 Annual Meeting, 8–12 March 8-12, 2024, San Diego, USA.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement